Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a contract development and manufacturing organization, has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, PA. According to the terms of the agreement, PEL, through one of its affiliates, would acquire at closing a 100% stake in the entity that operates the facility and owns the related real estate.
This acquisition broadens the offering of Piramal Pharma Solutions (PPS) by adding solid oral dosage form capabilities (tablets and capsules) in North America. Until now, PPS’ capabilities in solid oral dosage forms were all located in the UK and India. The Sellersville site can also produce liquids, creams, and ointments, further expanding the PPS portfolio. Additionally, the site can support product and process development for solid oral dosage and oral liquids, including immediate release, modified release, chewable & sublingual solid oral dosage forms, solutions and suspensions in liquids, and the site has received certifications from the FDA and EMA.
“Many of our customers are looking for U.S.-based manufacturing partners to expand and support their pipeline. This acquisition strengthens our ability to partner with them on best-in-class drug products. It enhances our market-leading integrated services offering by adding a solid oral dosage capability in the US. We now offer solid oral drug product development and commercial manufacturing in all our major geographies, addressing a previously unmet customer need and strengthening our ability to work globally with customers to reduce the burden of disease on patients,” said Peter DeYoung, CEO of Piramal Pharma Solutions
TheSellersville site covers 31.5 acres of land withover 221,000 square feet of manufacturing space, including 195,000 square feet of GMP area. The site features dedicated manufacturing and packaging technologies for solid oral dosage forms, liquids, creams, and ointments; QC and microbiology labs; state-of-the-art preformulation and analytical developmentinfrastructure coupled with apilot lab for research and development;and a temperature-controlled warehouse. The site currently has the necessary controls to support manufacturing of potent solid oral dosage forms.
PPS intends to offer high potency drug manufacturing capabilities at the site, complementing the Company’s global strength in highly potent compounds.The site employs a highly knowledgeable and experienced workforce of ~100, with an average of 19years of service with the site. PPS expects to further grow the site’scurrent strength to support development services as well as any COVID-19 management drug opportunities.Expanding the PPS service offeringsdirectly supports the Company’s philosophy of Patient Centricity. Understanding theneeds of patients and building an organization that is dedicated to addressing those needs is the foundation of Patient Centricity. By putting patients first, PPS isaligning itsmission with that of itscustomers, becoming better partners who share a common goal.
About Piramal Pharma Solutions:
Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.
